GSK Wagers On Cervarix In Head-To-Head Trial Against Merck’s Gardasil
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline raised the stakes behind its anticipated launch of the investigational cervical cancer vaccine Cervarix Jan. 18, announcing the initiation of the first head-to-head trial comparing it to Merck's Gardasil. The study will evaluate differences between the two vaccines in inducing strong and sustained immune responses to the human papilloma virus in women